Friedrich Reinhard

Friedrich Reinhard is working at Cellzome in Heidelberg/Germany since 2007. He started as group leader of the screening group where he was responsible for applying Cellzome’s Kinobeads technology to primary screening and lead optimisation. Following the acquisition of Cellzome by GSK in 2012, he took over responsibility for chemoproteomic technology projects and their application to drug discovery. This includes the extension of the cellular thermal shift assay (CETSA) methodology by mass spectrometry to enable the thermal profiling of cellular proteomes (TPP).